UK Covid live news: infections increase in England and Wales, ONS estimate shows; Pfizer jab approved for over-12s | Politics
We have carefully considered the younger age group and the benefits of this vaccination against the potential risk of side effects.
These data have undergone a thorough evaluation and review, which was also specifically examined by the CHM’s Expert Advisory Group on Pediatric Medicines, who are scientific experts in this age group, and by the CHM’s Expert Working Group on Covid-19 Vaccines.
We have concluded that based on the data we have on the quality, efficacy and safety of the vaccine, the benefit outweighs any risk.
The MHRA will continue to review all suspected adverse reactions data obtained through the strict monitoring program under the Yellow Card program and other safety monitoring measures for all Covid-19 vaccines used in the UK.
The randomized, placebo-controlled clinical trials examined over 2,000 children aged 12 to 15 years. From seven days after the second dose, there were no cases of Covid-19 in the vaccinated group compared to 16 cases in the placebo group.
In addition, data on neutralizing antibodies showed that the vaccine worked at the same concentration as it did in adults 16-25 years of age. These are extremely positive results.